NCT06557148Active, not recruiting
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
18F-Fluoroestradiol (FES) Positron Emission Tomography for the Detection and Treatment Response Monitoring in Patients With Metastatic Lobular Breast Carcinoma
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC. This study will compare PET/CT (positron emission tomography/computed tomography) scans using the radiotracer fluorine 18 (18F)-fluoroestradiol (FES) with a standard imaging approach for detecting and monitoring ILC, PET/CT scans using the radiotracer 18F-fluorodeoxyglucose (FDG). These scans will be referred to as FES PET/CT scans and FDG PET/CT scans.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 7 (actual)
- First submitted
- 13 Aug 2024
- Start date
- 13 Aug 2024
- Primary completion date
- 13 Aug 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06557148
What you commit to
- Study type: Observational
- Participants enrolled: 7
- From 13 Aug 2024 to the primary completion date, 13 Aug 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have been on adjuvant ER-blocking endocrine therapy with SERM or SERD without an 8- and 24-weeks washout, respectively. (The use of aromatase inhibitors or ovarian suppression is permitted given that they do not block estrogen receptors).
Other illness
- Patient presents with any other clinically active, serious, life-threatening disease, medical, or psychiatric condition, and/or who has a life expectancy of \<12 months, or for whom study participation may compromise their management; and/or a patient who the investigator judges to be unsuitable for participation in the study for any reason.
Other
- Low ER expression defined as ER \<10% of tumor cells by IHC
- Pregnancy or lactation or parturient or nursing mother
Who the study is looking for
- Adult patient \> 18 years old
- Biopsy-proven metastatic ILC
- Confirmed ER+ breast cancer from either primary tumor or metastatic biopsy (ER receptor percent staining ≥ 10% of tumor cells by IHC)
- HER2-negative per ASCO/CAP
- ECOG Performance Status Score of 0, 1 or 2.
- Patient can have received up to 2 lines of therapy in the metastatic setting
- Life expectancy of at least 12 months
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Coordinator of this site? Confirm its status | Basking Ridge | United States | Unknown status |
| Memorial Sloan Kettering Suffolk-Commack (All protocol activity) Coordinator of this site? Confirm its status | Commack | United States | Unknown status |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) Coordinator of this site? Confirm its status | Harrison | United States | Unknown status |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Coordinator of this site? Confirm its status | Middletown | United States | Unknown status |
| Memorial Sloan Kettering Bergen (All Protocol Activities) Coordinator of this site? Confirm its status | Montvale | United States | Unknown status |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Memorial Sloan Kettering Nassau (Limited Protocol Activites) Coordinator of this site? Confirm its status | Rockville Centre | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.